PET

EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER'S DISEASE TO BETTER SERVE PATIENTS

Retrieved on: 
Tuesday, March 5, 2024
Collection, Senior, Alzheimer's disease, Pathology, Cerebrospinal fluid, Eisai, Growth, Amyloid, Headquarters, Clinical, Dementia, Patient, CSF, Diagnosis, PET, Environment, Medical imaging

By investing in C2N, Eisai seeks to support efforts to advance blood-based Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.

Key Points: 
  • By investing in C2N, Eisai seeks to support efforts to advance blood-based Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.
  • "The field of highly accurate blood-based diagnostics is rapidly advancing and expanding," said Keisuke Naito, Global Alzheimer's Disease Officer, Senior Vice President, Eisai.
  • "Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem's growth.
  • The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer's disease."

Industry Leaders Announce the Cardiac PET Industry Coalition (CPIC)

Retrieved on: 
Tuesday, March 5, 2024
Marketing, Coalition, Nuclear medicine, Multimedia, CMS, Cardiovascular disease, Human, Medicare, CPIC, Health, Patient, Policy, Heart, Bracco (company), Congress, Molecular imaging, Siemens Healthineers, PET, Medical imaging

WILMINGTON, Del., March 5, 2024 /PRNewswire-PRWeb/ -- Leading manufacturers in cardiac positron emission tomography (PET) imaging launched the Cardiac PET Industry Coalition (CPIC), an initiative dedicated to promoting federal policies that advance health outcomes for patients with cardiovascular disease and the availability of cardiac PET diagnostics. CPIC will champion fair and transparent coverage and reimbursement policies that facilitate access to cardiac PET, align practitioners with regard to research opportunities, highlight the clinical and economic benefit of this modality, and provide expanded opportunities to educate healthcare providers and policymakers on the overall value of cardiac PET.

Key Points: 
  • WILMINGTON, Del., March 5, 2024 /PRNewswire-PRWeb/ -- Leading manufacturers in cardiac positron emission tomography (PET) imaging launched the Cardiac PET Industry Coalition (CPIC) , an initiative dedicated to promoting federal policies that advance health outcomes for patients with cardiovascular disease and the availability of cardiac PET diagnostics.
  • "The clinical benefits of cardiac PET imaging are well-documented for making patient care and treatment decisions.
  • "I'm proud of the work the Coalition is doing to increase awareness, maintain appropriate reimbursement and expand the adoption of cardiac PET imaging."
  • Phil Cranmer, Cardiac PET Industry Coalition (CPIC), 1 (215) 888-0040, [email protected] , https://cpicoalition.com/
    View original content to download multimedia: https://www.prweb.com/releases/industry-leaders-announce-the-cardiac-pet...

Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer's Disease, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, March 5, 2024
LP, Alzheimer's disease, Doctor of Philosophy, MD, Pathology, PET, Cerebrospinal fluid, Diagnosis, Amyloid, Biomarker, DMTS, Deficit spending, Health, Associate, Patient, CSF, Brain, Medical imaging

TORONTO, March 5, 2024 /PRNewswire-PRWeb/ -- The availability of disease-modifying treatments (DMTs) for early symptomatic Alzheimer's disease (AD) has greatly increased the need for clinical AD biomarker testing, which is helpful for determining whether cognitive impairment is caused by AD brain pathology or some other condition. Biomarker evidence of amyloid pathology is essential before the initiation of AD DMTs. This webinar will review the types of AD biomarker tests that are clinically available, including cerebrospinal fluid (CSF) biomarkers, amyloid positron emission tomography (PET) and AD blood tests.

Key Points: 
  • In this free webinar, learn about different Alzheimer's disease (AD) biomarker testing modalities, and the particular promise of high-performance AD blood tests.
  • Attendees will also learn about the variability in the diagnostic performance of AD blood tests and how performance affects the clinical use of tests.
  • This webinar will review the types of AD biomarker tests that are clinically available, including cerebrospinal fluid (CSF) biomarkers, amyloid positron emission tomography (PET) and AD blood tests.
  • Register for this webinar to learn more about different AD biomarker testing modalities, and the particular promise of high-performance AD blood tests.

SK chemicals, Hyosung Advanced Materials, and Hankook Tire Commercialize South Korea's First Chemically Recycled PET Tire

Retrieved on: 
Tuesday, March 5, 2024
Carbon, Hankook Tire, Certification, Multimedia, RED, PLUS, ISCC, Safety, Plastic, Tire, Recycling, PET

SEONGNAM, South Korea, March 5, 2024 /PRNewswire/ -- To reduce carbon emissions, the South Korean industrial sector has developed and commercialized the country's first tire using chemically recycled PET.

Key Points: 
  • SEONGNAM, South Korea, March 5, 2024 /PRNewswire/ -- To reduce carbon emissions, the South Korean industrial sector has developed and commercialized the country's first tire using chemically recycled PET.
  • SK chemicals (CEO Ahn Jae-hyun), Hyosung Advanced Materials Co., Ltd. (CEO Cho Yong-soo), and Hankook Tire & Technology Co., Ltd. (CEO Lee Soo-il, hereafter Hankook Tire) announced on the 5th that they have successfully developed the electric vehicle-exclusive tire "iON" applying "circular recycled PET (polyester) fiber tire cords."
  • SK chemicals, Hyosung Advanced Materials, and Hankook Tire have collaboratively developed this tire over a period of about two years.
  • SK chemicals has reliably supplied the circular recycled PET "SKYPET CR", and Hyosung Advanced Materials developed the high-strength recycled PET-based tire cords using this as a raw material.

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

Retrieved on: 
Tuesday, March 5, 2024
Diagnosis, Isotope, Therapy, PET, Research, SPECT, Pharmaceutical industry

With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.

Key Points: 
  • With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.
  • Furthermore, the new laboratory will allow Ariceum to conduct non-clinical pharmacology studies for detailed characterization of its first-in-class development candidates.
  • Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: "Following 15 months of construction at our headquarters in Berlin, we are delighted to have opened our brand new, advanced laboratory space.
  • We are very grateful to our team in Berlin who have pushed hard to bring these construction plans to fruition."

Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities

Retrieved on: 
Tuesday, March 5, 2024
Diagnosis, Isotope, Therapy, PET, Research, SPECT, Pharmaceutical industry

With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.

Key Points: 
  • With the new facility, Ariceum has more than ~200m² of laboratory space (cold biology/chemistry lab; radioactive lab) to which a further ~60m² of changing lock and storage space can be added.
  • Furthermore, the new laboratory will allow Ariceum to conduct non-clinical pharmacology studies for detailed characterization of its first-in-class development candidates.
  • Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, said: "Following 15 months of construction at our headquarters in Berlin, we are delighted to have opened our brand new, advanced laboratory space.
  • We are very grateful to our team in Berlin who have pushed hard to bring these construction plans to fruition."

SK chemicals, Hyosung Advanced Materials, and Hankook Tire Commercialize South Korea's First Chemically Recycled PET Tire

Retrieved on: 
Tuesday, March 5, 2024
Hankook Tire, Carbon, ISCC, Safety, Plastic, Recycling, PET

SK chemicals (CEO Ahn Jae-hyun), Hyosung Advanced Materials Co., Ltd. (CEO Cho Yong-soo), and Hankook Tire & Technology Co., Ltd. (CEO Lee Soo-il, hereafter Hankook Tire) announced on the 5th that they have successfully developed the electric vehicle-exclusive tire "iON" applying "circular recycled PET (polyester) fiber tire cords."

Key Points: 
  • SK chemicals (CEO Ahn Jae-hyun), Hyosung Advanced Materials Co., Ltd. (CEO Cho Yong-soo), and Hankook Tire & Technology Co., Ltd. (CEO Lee Soo-il, hereafter Hankook Tire) announced on the 5th that they have successfully developed the electric vehicle-exclusive tire "iON" applying "circular recycled PET (polyester) fiber tire cords."
  • SK chemicals, Hyosung Advanced Materials, and Hankook Tire have collaboratively developed this tire over a period of about two years.
  • SK chemicals has reliably supplied the circular recycled PET "SKYPET CR", and Hyosung Advanced Materials developed the high-strength recycled PET-based tire cords using this as a raw material.
  • The iON model developed by Hankook Tire incorporates 45% sustainable materials, including bio-based, circular, and bio-circular polymers, bio-based silica along with Hyosung Advanced Materials' tire cords, and the model is the first tire to bear the ISCC PLUS certification logo.

Chlorophyll Water to Debut New Bottles Made from 100% Recycled Plastic with CleanFlake at Natural Products Expo West

Retrieved on: 
Monday, March 4, 2024
Sprouts, Pura, RPET, Social media, Certification, EFSA, Body, Erewhon, Pesticide, Health, Water, Sprouts Farmers Market, Meijer, Nature, Food, Carbon, Bottle, Drink, Central Market, Earth Fare, Plasticizer, CO2, GIANT, United, Reverse vending machine, Mind, European Food Safety Authority, Bristol Farms, Recycling, Publication, PET, Environment, Bottled water

Natural's Product Expo is the largest natural, organic and healthy products event in the United States.

Key Points: 
  • Natural's Product Expo is the largest natural, organic and healthy products event in the United States.
  • No adhesive residue remains on the plastic, meaning it can be processed into clean, high quality, recycled PET flakes.
  • CleanFlake technology ensures that Chlorophyll Water's labels cleanly separate during the recycling process increasing the yields of pure PET flakes.
  • Chlorophyll Water is available at ChlorophyllWater.com , on Amazon.com/ChlorophyllWater and can be found on all social media platforms at @ChlorophyllWater.

Neurophet introduces AI-powered brain imaging analysis technology at AD/PD 2024

Retrieved on: 
Monday, March 4, 2024
Myenteric plexus, Artificial intelligence, ARIA, Observation, Prognosis, Patient, Donanemab, DSM-IV codes, Fifth, Atrophy, WMH, PET, MRI, Brain, Medical imaging

SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the international conference on Alzheimer's and Parkinson's diseases and related neurological disorders (AD/PD 2024).

Key Points: 
  • At this conference, Neurophet will introduce Alzheimer's disease treatment related technologies planned to be commercialized such as analysis of the side effect and amyloid-positive prediction.
  • Neurophet AQUA analyzes brain atrophy and white matter hyperintensities (WMH) found in brain MRI of most Alzheimer's disease patients.
  • Neurophet SCALE PET provides quantitative regional amyloid beta deposition, known as the causative agent of Alzheimer's disease, using PET images.
  • Neurophet plans to launch total solution for Alzheimer's disease treatment including ARIA analysis, since Neurophet has the technology to analyze ARIA.

Pop & Bottle Rolls Out New Organic Cold Brew Coffee Line, Amplifying Its Mission-Driven Ethos, At Select Stores Nationwide

Retrieved on: 
Monday, March 4, 2024
Cold brew coffee, Caffeine, Farmer, Female, Empowerment, Generation Z, Carbon, Coffee, Sustainable packaging, Milk, Pop, Starbucks, Male, SKU, Workforce, PET, Target

LOS ANGELES, March 4, 2024 /PRNewswire/ -- Female-founded Pop & Bottle, known for its delicious, nourishing plant-based lattes and coffee concentrates, announces the launch of Organic Cold Brew Coffee in a 48oz, multi-serving bottle. Available today in the refrigerated aisles at select Target stores nationwide, this offering is available in Light Roast, Medium Roast and Vanilla varieties. Each SKU is unsweetened and has moderate caffeine levels, offering ultimate customization, ease and convenience for the daily coffee ritual.

Key Points: 
  • LOS ANGELES, March 4, 2024 /PRNewswire/ -- Female-founded Pop & Bottle, known for its delicious, nourishing plant-based lattes and coffee concentrates, announces the launch of Organic Cold Brew Coffee in a 48oz, multi-serving bottle.
  • Available today in the refrigerated aisles at select Target stores nationwide, this offering is available in Light Roast, Medium Roast and Vanilla varieties.
  • "At Pop & Bottle, we believe your daily coffee ritual should be purposeful, nourishing and gratifying," says Jash Mehta, Pop & Bottle CEO and co-founder.
  • Pop & Bottle's Cold Brew Coffee stands out not just for its premium taste but for its commitment to female empowerment and environmental ethos.